A Fresh Surge for New River
Just when investors in New River Pharmaceuticals (NRPH) thought things couldn't get any better, they did. Following a surge of more than 60% on Oct. 9 after the company announced an approvable letter from the Food and Drug Administration for its treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12, the shares zoomed again on Oct. 10, rising 6.94 to 49.26. The reason? Details of the company's profit-sharing arrangement with its collaborative partner Shire PLC (SHPGY) released in an SEC filing on Oct. 10.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.